ArticleCancer biomarkers : section A of Disease markers2023
Hsa_circ_0070661 inhibits cancer progression through miR-556-5p/TEK axis in lung adenocarcinoma.
Article in Cancer biomarkers : section A of Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Unveiling hsa_circ_0007439: a novel suppressor of nasopharyngeal carcinoma via miR-556-5p/PTEN Axis.Discover oncology · 2024Article
- Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.Cancer cell international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) has a high incidence and poor prognosis, and multiple circRNAs (circRNAs) have been found to regulate LUAD.
objectiveThis study focuses on the effect and mechanism of hsa_circ_0070661 in LUAD.
methodsLUAD tissues and para-cancerous tissues were collected from 38 patients diagnosed with LUAD in our hospital. Hsa_circ_0070661, miR-556-5p and TEK Receptor Tyrosine Kinase (TEK) levels were evaluated using western blotting and RT-qPCR, and the targeting relationship was detected by luciferase reporter and RIP assays. Cell migration, viability, apoptosis-related proteins, (Bcl-2 and Bax) and tumor growth in vivo were assessed by Transwell, CCK-8, western blotting and xenograft assays, respectively.
resultsResults indicated downregulation of hsa_circ_0070661 and TEK in LUAD cell lines and tissues, whereas upregulation of miR-556-5p. Hsa_circ_0070661 upregulation restrained the viability, migration and tumor growth of LUAD cells, and promoted apoptosis. Hsa_circ_0070661 could directly target miR-556-5p to upregulate TEK expression in LUAD. MiR-556-5p upregulation promoted the malignant phenotypes of LUAD cells and reversed the anti-cancer effect of hsa_circ_0070661 overexpression, while TEK upregulation inhibited LUAD progression and somewhat eradicated the cancer-promoting effect of miR-556-5p upregulation.
conclusionsHsa_circ_0070661 sponges miR-556-5p to inhibit LUAD development via regulating TEK, providing a promising molecular target for LUAD clinical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.